CNBG is a pharmaceutical company with a long-standing history of vaccine development in China. It rose to prominence during COVID-19 as one of the major COVID-19 vaccine providers, namely, Sinopharm BBIBP vaccine which has been supplied for over 200 million doses. On 7 May 2021, the WHO has officially approved the BBIBP vaccine for emergency use.

Innova Medical Group on the other hand, developed an end-to-end ecosystem of rapid diagnostic and screening tests, along with digital reporting and tracing applications to help organizations manage the COVID-19 crisis. In 2020, Innova delivered more than 220+ million COVID-19 test kits to over 20 countries around the globe, including the United Kingdom, Hungary, Singapore, United Arab Emirates and Myanmar.

Sino-Innovax is birthed when preparation meets opportunity. Learning from the lessons of COVID-19, both parent companies want to further focus on the R&D of pharmaceuticals and vaccines to prepare for a better tomorrow. We bring together the science, talents and business network to add value into patient’s lives. Sino-Innovax focuses on providing a global platform for products and technologies from CNBG, starting from the unique strategic position of Singapore. We strive to provide access to quality and affordable products to millions of people worldwide.